Why Is MAPLIGHT THERAPEUTIC (MPLT) Stock Moving Today?

Why MPLT stock is moving today

MapLight Therapeutics (MPLT) shares are moving sharply lower today, down from an opening gap of +3.9% to a session low of $9.71, a drop of over 75% from the opening price. The stock's dramatic intraday move follows mixed data from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia. While the trial met its primary endpoint with the 210/3 mg twice-daily dose, the 330/6 mg once-daily dose missed the primary endpoint. This outcome has triggered analyst reactions and investor uncertainty.

What Happened

The ZEPHYR trial showed statistically significant improvements in cognitive function and efficacy for the twice-daily dose of ML-007C-MA, which could be a meaningful development for schizophrenia treatment. However, the failure of the once-daily formulation to meet the primary endpoint has raised concerns about the drug’s practicality and commercial potential. This led to a Reuters report noting that MapLight’s shares plunged following the news. Analysts have responded with mixed reactions: Wolfe and Raymond James cut their price targets, while BMO and Stifel maintained their positive ratings. Jefferies also reiterated its stance, suggesting the data is still seen as valuable despite the setback.

What The Data Shows

MPLT is trading at $9.76 as of the latest update, significantly below its 52-week high of $40.43 and above its $12.24 low. The stock has seen unusually high volume today, with 7.0 million shares traded, 18.2 times the 3-month daily average. This suggests a sharp shift in sentiment among traders. In addition, insider selling has been notable in recent weeks, with 11 sales totaling $16.9 million reported on SEC Form 4 filings. The most recent sales occurred on July 15 by key executives including the Chief Medical Officer and Chief Discovery Officer.

What To Watch

MapLight Therapeutics does not have an upcoming earnings report on the calendar. Investors should monitor analyst coverage and any follow-up data releases, as well as potential reactions from the broader market to the ZEPHYR results.